Roche/Astellas Pharma Inc.’s filing for Tarceva (erlotinib) as a first-line therapy in patients with EGFR-activating mutations could establish the drug more firmly in one of the largest non-small-cell lung cancer disease subtypes.
Astellas announced Nov. 20 that it submitted a supplemental NDA for Tarceva as a first-line therapy in EGFR-mutation positive locally...